Encorafenib,Cetuximab,Binimetinib
Pfizer,Eli Lilly,Array Biopharma
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'beacon']
beacon translational analyses shared by : subclonal mapk pathway activation with multiple acquired alterations (ras/braf mutations, met amplification ) as the main escape mechanism to braf/egfr+/-mek inhibition in braf v600 mutated mcrc 
GI oncologist, MD, PhD (FRA)